DOXEPIN HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for doxepin hydrochloride and what is the scope of patent protection?
Doxepin hydrochloride
is the generic ingredient in four branded drugs marketed by Adaptis, Aiping Pharm Inc, Ajanta Pharma Ltd, Alembic, Amneal Pharms Co, Appco, Aurobindo Pharma Ltd, Chartwell Rx, Dava Pharms Inc, Endo Operations, Epic Pharma Llc, Jubilant Cadista, Lannett Co Inc, Leading, Mankind Pharma, Micro Labs, MSN, Mylan Pharms Inc, New River, Purepac Pharm, Quantum Pharmics, Sandoz, Sun Pharm Industries, Taro, Unique Pharm, Velzen Pharma Pvt, Watson Labs, Watson Labs Teva, Zydus Lifesciences, Pfizer, Pharm Assoc, Pharmobedient Cnsltg, Teva Pharms, Amneal, Mylan, Actavis Elizabeth, Rk Pharma, Strides Pharma, and Currax, and is included in eighty-one NDAs. There are fifteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Doxepin hydrochloride has sixteen patent family members in four countries.
There is one drug master file entry for doxepin hydrochloride. Fifty suppliers are listed for this compound.
Summary for DOXEPIN HYDROCHLORIDE
International Patents: | 16 |
US Patents: | 15 |
Tradenames: | 4 |
Applicants: | 39 |
NDAs: | 81 |
Drug Master File Entries: | 1 |
Finished Product Suppliers / Packagers: | 50 |
Raw Ingredient (Bulk) Api Vendors: | 156 |
Clinical Trials: | 22 |
Patent Applications: | 1,361 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DOXEPIN HYDROCHLORIDE |
What excipients (inactive ingredients) are in DOXEPIN HYDROCHLORIDE? | DOXEPIN HYDROCHLORIDE excipients list |
DailyMed Link: | DOXEPIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DOXEPIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Nanfang Hospital, Southern Medical University | N/A |
Hematology Center after Prof. R. Yeolyan | Phase 1/Phase 2 |
E2Bio Life Sciences, LLC | Phase 1/Phase 2 |
Pharmacology for DOXEPIN HYDROCHLORIDE
Drug Class | Tricyclic Antidepressant |
Medical Subject Heading (MeSH) Categories for DOXEPIN HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for DOXEPIN HYDROCHLORIDE
Paragraph IV (Patent) Challenges for DOXEPIN HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SILENOR | Tablets | doxepin hydrochloride | 3 mg and 6 mg | 022036 | 2 | 2010-09-16 |
US Patents and Regulatory Information for DOXEPIN HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Pharms Inc | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CAPSULE;ORAL | 070791-002 | May 13, 1986 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Mylan Pharms Inc | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CAPSULE;ORAL | 070791-005 | May 13, 1986 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Micro Labs | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CAPSULE;ORAL | 217688-004 | Jun 27, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Quantum Pharmics | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CAPSULE;ORAL | 072375-001 | Mar 15, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DOXEPIN HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Currax | SILENOR | doxepin hydrochloride | TABLET;ORAL | 022036-001 | Mar 17, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Mylan | ZONALON | doxepin hydrochloride | CREAM;TOPICAL | 020126-001 | Apr 1, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Currax | SILENOR | doxepin hydrochloride | TABLET;ORAL | 022036-002 | Mar 17, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Currax | SILENOR | doxepin hydrochloride | TABLET;ORAL | 022036-002 | Mar 17, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DOXEPIN HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2007142810 | ⤷ Sign Up | |
Japan | 2016041757 | ⤷ Sign Up | |
Japan | 2013237694 | ⤷ Sign Up | |
European Patent Office | 2148659 | FORMULATIONS DE DOXÉPINE À FAIBLE DOSE ET PROCÉDÉ DE PRÉPARATION ET D'UTILISATION DE CELLE-CI (LOW-DOSE DOXEPIN FORMULATIONS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.